Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00824824 · ClinicalTrials.gov registry record · NA
Effect of Cosopt Versus Combigan on Retinal Vascular Autoregulation in Primary Open Angle Glaucoma (POAG)
A NA study of Glaucoma, sponsored by Massachusetts Eye and Ear Infirmary.
- Completed
- Registry status
- NA
- Development phase
- 21
- Enrollment target
- 1
- Study location
NCT00824824: Completed NA study of Glaucoma, sponsored by Massachusetts Eye and Ear Infirmary.
NCT00824824 is a NA study of Glaucoma that has completed, run by Massachusetts Eye and Ear Infirmary. The registered enrollment target is 21 participants, below the 910-participant average among 92 other Glaucoma trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00824824, a NA study of Glaucoma, has completed, sponsored by Massachusetts Eye and Ear Infirmary.
- COMPLETED
- Registry status
- NA
- Development phase
- 21 participants
- Enrollment target
- 1
- Study location
Study Summary
We have completed a study in which we examined the response of the retinal circulation to changes in posture from sitting to lying down in patients with primary open angle glaucoma (POAG). This alteration in position produces changes in the local blood pressure at the entrance to the retinal vasculature. In a healthy retina, the vasculature adapts by dilating and constricting in order to maintain a steady blood flow rate. In an eye with POAG, this often does not occur. As a result, there are large fluctuations in blood flow which may produce the retinal neuronal damage associated with glaucoma. The purpose of this study is to demonstrate that topical anti-glaucoma treatments with agents that have vasoactive as well as IOP-lowering effects can have a beneficial effect on maintaining a steady retinal blood flow rate even when there are changes in local blood pressure.
Primary Outcome
We determined whether RVD was present in the following way. The difference between the retinal blood flow measured while reclining for 30 minutes and the baseline retinal blood flow measured while seated was calculated. In a previous study, we found that among healthy subjects the change in the blood flow while reclining compared to baseline was +6.5% ± 12%. For this study, we defined the normal range of blood flow autoregulation as ± 2 standard deviations about the mean percentage change found
Conditions Studied
Interventions
- DRUG Dorzolamide 2%-timolol 0.5%
- DRUG Brimonidine 0.2%-0.5% timolol 0.5
Study Locations (1)
Massachusetts
- Massachusetts Eye and Ear Infirmary - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 21 participants |
| Start Date | 2009-01 |
| Est. Completion | 2012-08 |
| Phase | NA |
What the finished NCT00824824 record still lists
NCT00824824 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 21 participants, a relatively small participant target, below the 910-participant average among 92 other Glaucoma trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Glaucoma appearing as the primary indexed condition, and to 2 interventions - of which Dorzolamide 2%-timolol 0.5% is the first listed.
NCT00824824 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT00824824 about?
NCT00824824 is a clinical study titled "Effect of Cosopt Versus Combigan on Retinal Vascular Autoregulation in Primary Open Angle Glaucoma (POAG)". We have completed a study in which we examined the response of the retinal circulation to changes in posture from sitting to lying down in patients with primary open angle glaucoma (POAG). This alteration in position produces changes in the local blood pressure at the entrance to the retinal vascula...
What is the current status of trial NCT00824824?
This trial is currently completed. It is a NA study. The enrollment target is 21 participants. The study started on 2009-01. Estimated completion is 2012-08.
What conditions does trial NCT00824824 study?
This clinical trial studies the following conditions: Glaucoma.
What interventions are being tested in trial NCT00824824?
The interventions under investigation include: Dorzolamide 2%-timolol 0.5% (DRUG), Brimonidine 0.2%-0.5% timolol 0.5 (DRUG).
Who is sponsoring clinical trial NCT00824824?
This trial is sponsored by Massachusetts Eye and Ear Infirmary, which has 73 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00824824 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glaucoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00824824's enrollment target sits among peer trials
21 86th of 92 higher than 7 of 92 other Glaucoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glaucoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Village-Integrated Eye Worker Trial II
RECRUITING · NA
-
Tolerability of an Anesthesia-free Tonometer Tip
RECRUITING · NA
-
Electrical Stimulation for the Treatment of Optic Neuropathies
RECRUITING · NA
-
The Role of Music in Enhancing Attention During Visual Field Exams for Pediatric Glaucoma Patients
RECRUITING · NA
-
Electrical Stimulation for the Treatment of Glaucoma
RECRUITING · NA
-
Hyperbaric Oxygen Therapy for Optic Neuropathies
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02447874 · 21 participants · Phase 1
Arginine Therapy for the Treatment of Pain in Children With Sickle Cell Disease
- NCT03826992 · 21 participants · Phase 1
Venetoclax Combined With Vyxeos (CPX-351) for Participants With Relapsed or Refractory Acute Leukemia
- NCT04107077 · 21 participants · Phase 2
Phase II Study of the Effects of Laparoscopic Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Patients With Advanced Gastric Cancer
- NCT04158635 · 21 participants · Phase 1
Gemcitabine, Nab-Paclitaxel, and Bosentan for the Treatment of Unresectable Pancreatic Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia